Heart Decompensation
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Tenax TherapeuticsCHAPEL HILL, NC
1 programLevosimendanN/A1 trial
Active Trials
NCT02973620No Longer Available
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
BayerMultiple intervention program
Clinical Trials (2)
Total enrollment: 25 patients across 2 trials
Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
N/ANo Longer Available
RAndomized Controlled Trial of a Multiple INtervention proGram to Decrease Heart Failure Rehospitalization
Start: Jul 2022Est. completion: Sep 202425 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space